Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

353 results about "Sexual functioning" patented technology

Synthesis of selective androgen receptor modulators

InactiveUS7759520B2Low yieldHighly pure productsBiocideOrganic active ingredientsAging maleProstate cancer incidence
The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen relacement and / or other clinical therpauetic and / or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.
Owner:UNIV OF TENNESSEE RES FOUND

Multi-substitued selective androgen receptor modulators and methods of use thereof

This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscular wasting conditions; e) preventing and / or treating dry eye conditions; f) oral androgen replacement therapy; and / or g) decreasing the incidence of, halting or causing a regression of prostate cancer.
Owner:UNIV OF TENNESSEE RES FOUND

Compositions and methods related to heart failure

The invention provides methods for (a) prolonging time to hospitalization for heart failure; (b) prolonging time to first hospitalization for heart failure; (c) reducing the total number of days a patient with heart failure spends in the hospital for heart failure for a single hospital stay (i.e., reducing the duration of a single hospital stay for a patient with heart failure); (d) reducing the total number of days a patient spends in the hospital for heart failure for multiple hospital stays (i.e., two or more hospital stays); (e) reducing the number of hospital admissions for heart failure; (f) reducing mortality and reducing hospitalizations for heart failure (e.g., the total number of days in the hospital and / or the number of hospital visits); (g) increasing the left ventricular ejection fraction in a heart failure patient; (h) treating a sexual dysfunction (e.g., erectile dysfunction and female sexual dysfunction) (j) treating a headache in a heart failure patient by administering a non-steroidal antiinflammatory compound (i.e., NSAIDs); (k) treating a heart failure patient who has a history of hypertension (but who is not currently diagnosed with hypertension); (l) improving the quality of life in a heart failure patient based on the Minnesota Living with heart failure questionnaire; (m) decreasing the levels of B-type natriuretic peptide; (n) treating hypertension in a heart failure patient; (o) lowering blood pressure in a heart failure patient; (p) treating labile hypertension; (q) treating idiopathic hypertension; (r) increasing patient compliance with medication dosing in a heart failure patient; (s) treating hypertension in a patient with a dilated heart; (t) treating ischemic disease and / or coronary artery disease; and (u) reducing cardiomegaly in a patient in need thereof comprising administering to the patient a therapeutically effective amount of (i) a hydralazine compound or pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and / or isosorbide mononitrate, and (iii) optionally at least one compound selected from the group consisting of angiotensin converting enzyme inhibitors, β-adrenergic antagonists, angiotensin II antagonists, aldosterone antagonists, cardiac glucosides (digitalis), and diuretic compounds.
Owner:NITROMED

Maca superfine powder as well as preparation method and application thereof

The invention discloses maca superfine powder as well as a preparation method and application thereof. The grain size of the maca superfine powder is measured by a dry method laser granulometry meter and is 0.5-3 micrometers. The preparation method of the powder comprises the following steps: 1 removing impurities and cleansing; 2 freeze-drying, and carrying out sterilization treatment after drying; 3 grinding dry maca powder into coarse powder, then carrying out superfine-grinding in a jet mill, and thus obtaining the superfine powder with the grain size being 0.5-3 micrometers. The conditions of superfine-grinding are as follows: the grinding temperature is 18-25 DEG C, the pressure of a superfine-grinding machine when the powder enters the superfine-grinding machine is 1.5-3Mpa, the grinding pressure is 3-7Mpa, the airflow velocity is 190-300m/s, and the grinding time is 1-3h. The maca superfine powder is used for treating low immunity, physical fatigue and sexual dysfunction and has the advantages of being significant in curative effect and stable in condition of patients, improving the survival quality of patients, increasing the weight of patients, improving the immunologic function of patients, and being safe in medication.
Owner:SHANGHAI JINCHENG PHARMACEUTICAL CO LTD

Jade-brewed wine and preparation process thereof

The invention discloses a jade-brewed wine characterized in that a brewing process of the wine comprises a step that fermentation and aging are carried out in a wine cellar containing jade, such that the jade-brewed wine is obtained. A jade-brewed wine preparation process is characterized in that, according to a fen-flavor highland barley liquor production process, high-quality highland barley and peas are selected as raw materials; an entire process of steaming, bacteria culture saccharification, fermentation, and distillation are carried out under a solid state; and fermentation and aging are carried out in a jade wine cellar for more than 3 months, such that the jade-brewed wine is obtained. The jade-brewed wine contains trace elements necessary for human bodies, and has functions of disease preventing, aging resisting, skin beautifying, tumor resisting, and life prolonging. With the wine, organ functions can be comprehensively regulated, brainpower can be enhanced, physical work capacity can be enhanced, and energy can be promoted. The wine has kidney-nourishing and yang-tonifying functions. When the wine is taken for a long time, problems such as sexual impotence, premature ejaculation, and sexual dysfunction can be treated; heart and brain blood supply can be increased; heart and brain function can be improved; blood lipid can be reduced, and cardiovascular and cerebrovascular diseases can be prevented. The wine also has anti-wrinkle and anti-aging functions. With the wine, skins can maintain young.
Owner:HUZHU GUANZHI HIGHLAND BARLEY BIOLOGICAL INDZATION TECH RES & DEV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products